Ensign Plants a Flag in Florida — and Quietly Retires Three Old Worries
A guidance raise built on a record-quality core, a first-ever Sunshine State beachhead, and a call noticeably emptier of the words that used to dominate it
ENSG · Earnings Call · 2026-10-28
Planting the flag in the litigation state
On the surface this was a clean beat-and-raise. Adjusted diluted EPS of $2.03 rose 23.8%, revenue of $1.48 billion rose 14.5%, and full-year guidance moved up to $7.94–$8.02 from $7.75–$7.85 — a midpoint management pegs at +21.5% over 2025 and +45.1% over 2024. But the real news wasn't the number. It was the map.
Ensign added 22 operations during the quarter and since: nine in Florida, seven in Colorado, four in Washington and two in Texas — 2,370 new skilled nursing beds plus 113 independent living beds. Florida is a first for the company, and it shows up clearly in the keyword trajectory as a fresh, company-unique theme: Florida arrives as one of this quarter's biggest gainers, following the trail blazed a quarter earlier by new state entry generally (South Carolina was the 2026Q3 headline). This is the third or fourth consecutive quarter in which the expansion story has migrated to a new geography, and it is now 22% of the entire portfolio by operation count.
What makes it more than a footprint datapoint is Florida's reputation. Barry Port did not soft-pedal it:
The litigation environment is really busy. and that makes it sort of a deterrent for operators to come into the state. Certainly, 1 of the major red flags that we have looked at over time. But that all aside, it is a really great rate environment now. it is much more stable than it used to be. it is a good labor environment.
That is a company deliberately buying into the toughest tort environment in the country because the rate and labor backdrop finally compensate — and because a long-tenured internal leader, Forrest Peterson, moved down early in the year to build the market. The units themselves are archetypal Ensign: physical plant and clinical and financial distress all at once. Port was blunt that the Texas buildings acquired earlier are “still not accretive, but we expect that they are gonna come in way ahead of pro forma,” — Barry R. Port, CEO · 2026-10-28 and that Florida will take a year or more before it contributes.
The words that vanished
The most interesting thing about this transcript is what isn't in it. Three themes that dominated prior calls have simply gone silent.
First, clinical review intensity. In May, Ben Hendrix pressed on managed care plans tightening review to protect margin, and Barry pushed back hard: “I just think the comments around clinical review are being a bit overblown. It's really not a new phenomenon.” — Barry Port, President · 2026-05-01 That keyword topped the company's thematic list in 2026Q2. It does not appear in the Q3 ranking at all.
Second, agency labor and wage inflation. Across 2025 the calls were peppered with contract labor, agency utilization, wage trends and turnover. Spencer's line in November — “We are using some contract labor. It's very, very minimal. It's less than 1/5 of what we used just a couple of years ago,” — Spencer Burton, Chief Operating Officer · 2025-11-04 — was the last real airing of the subject. In Q3 2026 there is no agency discussion; labor is now framed entirely as a quality asset: RN retention 11% better than the 18-state average, administrator turnover 45% below the CMS state average.
Third, Medicare Advantage migration as a threat, which hasn't led the keyword list since 2024Q3.
What replaced them is a quality-as-moat narrative — quality measure ratings, CMS star distribution, survey performance — and a harder claim: that clinical outcomes are the mechanism by which census and acuity are won. The proof point is skill mix. Raj Kumar noted same-store skilled mix has held above the 32% mark, a level last seen during the COVID waiver era. Port's answer leaned on the calendar: “we are doing this in the third quarter, which is typically 1 of our weaker quarters,” — Barry R. Port, CEO · 2026-10-28 and Suzanne Snapper closed the loop — “it is all payers. We are not seeing it in 1 payer and not in the other payers.” — Suzanne D. Snapper, CFO · 2026-10-28 Broad-based payer growth is a meaningfully different claim than share-taking from a single MCO, and it is the strongest single sentence on the call.
The arithmetic under the raise
Strip out the narrative and two things in the numbers deserve attention. The first is the expense line. Effective SG&A rose 24% year-over-year against revenue growth of 14.5% — and 16% sequentially. Service-center build-out, a bigger corporate footprint and Standard Bear administration all sit in there, but it is a trend worth watching if the turnaround drag persists through 2027. Revenue has compounded 768% over the sixteen-year series and operating margin has stabilized near 9.3%, but SG&A is the line that's moving.
The second is the balance sheet. Effective net cash has fallen to $181 million from a $515 million peak in 2024Q3 — a 65% drawdown — even as management touts dry powder and available capacity. Both are true: “we currently have more than $730 million of available capacity under our line of credit” — Suzanne D. Snapper, CFO · 2026-10-28 plus 165 debt-free owned assets. Leverage stays disciplined — interest coverage of 69x is a company with room to keep buying. But the direction of travel matters when Chad Keetch says “50 to 60 acquisitions a year is totally doable. If not more.” — Chad A. Keetch, Executive · 2026-10-28
One quiet signal of confidence: a $40 million repurchase, bigger than any quarter in the ten-year series, executed while the shares traded well below their March peak of $215.83.
Where the story actually stands
The tape has already noticed something. ENSG sits 14.7% below its 2026-03-02 high but has rallied 15.9% over the last 90 trading days — a re-rating in progress, not a broken chart. Yet the multiple has de-rated: price-to-earnings sits at 24.6x versus 32.4x in 2026Q1, and price-to-revenue of 1.7x is 12% below a year ago.
That is the real tension. Guidance went up, but not because the turnarounds are paying off — Port explicitly said they aren't. It went up because the core is running hot. “we really expect that our core business will continue to be strong,” — Suzanne D. Snapper, CFO · 2026-10-28 Snapper said, and the 84.0% same-store occupancy at the start of Q4 supports it. Florida and Texas are, for now, a call option on 2028 earnings rather than a 2027 contributor, funded by a balance sheet that is being drawn down but remains comfortably leveraged at roughly 2.0x lease-adjusted.
Ensign is riding no obvious macro wave — the market's thematic tape is buried in AI data center infrastructure and semiconductor capacity, nowhere near post-acute care. Its move is idiosyncratic: a decentralized operating model that buys the worst buildings in hard geographies and refuses to talk about labor, payer scrutiny, or managed care pushback anymore. Whether that silence is confidence or selective memory is the question the next two quarters will answer.